Scientific Program

Conference Series LLC Ltd invites all the participants across the globe to attend 6th World Pharmacists & Clinical Pharmacy Annual Congress (10 Plenary Forums - 1 Event)
Chicago, Illinois, USA.

Past Conferences Report

Submit your Abstract
or e-mail to

events@conferenceseries.com
pharmaceuticalsciences@conferencesmail.org
pharmacists@conferenceseries.net

Scientific Program Day 1
Scientific Program Day 2

Day 2 :

  • Clinical Pharmacy and Its Key Role in Treatment | Pharma Research & Development | Clinical Pharmacy | Clinical Pharmacy and Drug Reactions
Location: Prague Room
Speaker

Chair

Jeevana Jyothi B

Sri Padmavati Mahila Visvavidyalayam, India

Session Introduction

Norbert Nwankwo

University of Port Harcourt, Nigeria

Title: Digital signal processing-based techniques: Providing pharmacists with computerized procedures for investigations

Time : 11:15-11:45

Speaker
Biography:

Norbert Nwankwo holds BPharm degree and has completed MPhil and PhD in Bioinformatics from De Montfort University, Leicester, United Kingdom. He is a Campaigner for the computerization of bioassessments teaches Pharmaco-informatics, research methods, etc. at the University of Port Harcourt, Nigeria. He has invented five computer-aided biomedical/bioengineering devices including Computer-Aided Drug Resistance Calculator using Digital Signal Processing technique called Informational Spectrum Method. He has also developed other devices which include Computer-Aided Druggability Detector, Computer-Aided Vaccine Potency Assessor, Computer-Aided Pharmaco-Investigator and Computer-Aided Drug Potency Decoder.

Abstract:

Background: Pharmaceutical dispensing practice has benefited from computerized, motorized (robotics) and Information Technology-based devices including Automated Dispensing Cabinets. Such devices are needed for pharmacological assessments. We had already developed one called Computer-Aided Pharmaco-Investigator.

Aim: The purpose of this presentation is to demonstrate to pharmacists how Pharmaco-Investigator works using potency assessments of two Anti-retroviral agents called Enfuvirfide and Sifuvirfide, and their protein target, N-terminal Heptad Repeat (NHR).

Method: The sequences of above-named agents are processed using a Digital Signal Processing (DSP) approach called Informational Spectrum Method (ISM) and nine pharmacological (physio-chemical and structural) parameters engaged.

Discussion: As shown in table 1, Sifuvirtide demonstrated greater potency than Enfuvirtide. This is in accord with the outcome of previous clinical investigation. This procedure is employable on all drugs as they are known to be either proteins, have protein targets or proteins encircling them.

Conclusion: This computerized (rational) and reliable device, which is employable on all drugs and is based on DSP technique that has served mankind for decades in areas such as radar technology has the tendency to revolutionalize pharmacological assessments.

 

  • Hospital Pharmacy | Industrial Pharmacy | Community Pharmacy | Clinical Pharmacy Activities and Prescriptions
Location: Prague Room
Speaker

Chair

Sandra Cuellar

University of Illinois Hospital & Health Sciences, USA

Session Introduction

Zainab Said Muhammed Al Hashimy

Khoula Hospital, Oman

Title: Twelve years analysis of bacterial isolates and their antibiotics sensitivity in a tertiary care burns unit
Speaker
Biography:

Zainab Said Muhammed Al Hashimy is a Senior Specialized Pharmacist in Plastic and Hand surgery wards. She has developed her skills in Pharmacy Management since 2006 in running the OPD Pharmacies in the Tertiary Care Hospital, Khoula Hospital in Oman. She is a Member in Education and Training in Pharmacy Department. She has interest in bacterial resistance and antimicrobial stewardship. She is performing research in the uses of antibiotic in surgical prophylaxis.

Abstract:

The aim of this study was to review the changes in distribution of bacterial populations and their antibiotic sensitivity over 12 years in a tertiary care burn unit. Understanding the periodic variation of isolated microorganisms and their antibiotic sensitivity helps in selecting the appropriate antimicrobial therapy before culture and sensitivity is reported. It also aids the design of antibiotics protocols. The study was retrospective. The data were obtained from the computerized hospital medical record system and the burn unit records. Overall, Pseudomonas aeruginosa was the most commonly isolated microorganism followed by Staphylococcus aureus, Meticillin-resistant Staphylococcus aureus (MRSA) and the genus Acinetobacter. Acinetobacter isolation rose rapidly and became more prevalent than P. aeruginosa over the last three years. Other organisms became isolated more frequently, such as Klebsiella pneumoniae, but their overall prevalence was low. Pseudomonas species frequency of isolation declined. P. aeruginosa, MRSA and other microorganisms showed increasing sensitivity to a number of antibiotics. MRSA remained highly sensitive to vancomycin. Acinetobacter showed high resistance to all antibiotics tested except colistin. K. pneumoniae was highly resistant to most of the antibiotics tested except the carbapenems, but the resistance to carbapenems increased over time.

Lais S Amaral

University of Campinas, Brazil

Title: Capecitabine and Sorafenib: Incidence of hand-foot syndrome, adherence to treatment and quality of life in patients during chemotherapy
Speaker
Biography:

Lais S Amaral has completed her Bachelor’s degree in Pharmacy from University of Campinas, Brazil and is currently a Master's student at Pharmacology at School of Medical Sciences, University of Campinas, Brazil. Her research interests include pharmaceutical care in oncology, adverse drug reactions and biomarkers for adverse events.

Abstract:

Statement of the Problem: Capecitabine (CAP) and Sorafenib (SOR) are oral antineoplastics indicated for colorectal (CR) and gastric (ST) cancer and hepatocellular carcinoma (HCC), respectively. If not taken properly, the treatment may be at risk. The pharmacist develops an important role to guarantee the adherence to oral antineoplastics ensuring the right information which directly influences in treatment. The purpose of this study is to describe the patients in use of CAP and SOR, the incidence of hand-foot syndrome (HSF), adherence to therapy and quality of life (QoL).

Methodology & Theoretical Orientation: This is a prospective, longitudinal and observational study. The patients were followed up during three cycles of chemotherapy and analyzed for HFS incidence based on self-observation; knowledge to therapy with MedTake test; adherence to treatment with Morisky-Green test. QoL was analyzed before the first and after the third cycle of chemotherapy through the general EORTC-QLC-30 and specific questionnaires EORTC-QLC-ST-022 for ST, EORTC-QLC-CR-29 for CR for patients in treatment with CAP and, before and after the first cycle of chemotherapy through the general EORTC-QLC-30 and specific questionnaire EORTC-QLC-HCC-18 for patients in treatment with SOR for HCC.

Findings: The patients were male (CAP 53.85%; SOR 93.33%) Caucasian (CAP 76.92%; SOR 86.67%) and tumors were in advanced stages (CAP 53.85% stage IV; SOR 60.00% BCLC C). MedTake indicated a high knowledge to therapy and, in both cases; medicine dosage was the most common mistake. Morisky-Green also indicated a high adherence to both therapies but patients frequently forgot to take their medicines and were careless about the timetable. The QoL decreased in both cases and the HFS was common in patients taking CAP at the second and third cycles of chemotherapy.

Conclusion & Significance: QoL decreased despite the fact that the adherence to therapies was high.

Marilia B Visacri

University of Campinas, Brazil

Title: Low-dose oral acetylcysteine in the attenuation of cisplatin-induced nephrotoxicity: A randomized double-blind placebo-controlled pilot trial in patients with head and neck cancer
Speaker
Biography:

Marilia B Visacri has received her Bachelor’s degree in Pharmacy from the University of Campinas, Campinas, Brazil, in 2011 and MSc degree in Medical Sciences from the same university in 2013. She is currently pursuing her PhD degree in Sciences at School of Medical Sciences, University of Campinas, Brazil. Her research interests include clinical pharmacy, pharmaceutical care, adverse drug reactions, oncology, oxidative stress biomarkers and biomarkers for adverse events.

 

Abstract:

Statement of the Problem: Cisplatin chemotherapy induces oxidative stress and therefore has consequent toxicities. The main dose-limiting side effect of cisplatin is nephrotoxicity. The protective antioxidant role of acetylcysteine (NAC) on nephrotoxicity due to cisplatin has been reported in experimental models; however, its efficacy in patients has not been elucidated. The aim of this study was to evaluate the possible protective effect of low-dose oral NAC on cisplatin-induced nephrotoxicity in patients with head and neck cancer.

Methodology & Theoretical Orientation: This is a randomized double-blind placebo-controlled pilot trial conducted with 57 patients undergoing treatment with at least one of the three cycles of high-dose cisplatin chemotherapy, concomitant to radiotherapy. Patients were randomly assigned and were given: (1) NAC syrup, 600 mg orally once a day at night for 7 consecutive days (two days before the chemotherapy, on the day of chemotherapy and 4 days after chemotherapy), n=28; or (2) Placebo, administered similarly to NAC, n=29. Plasma levels of creatinine were monitored to assess nephrotoxicity. Creatinine clearance was estimated using the Cockroft-Gault formula. Severity was classified by Common Toxicity Criteria for Adverse Events (version 4, grade 0 to 4).

Findings: Patients from both groups had similar demographics and clinical characteristics (p>0.05). Throughout the treatment, elevated creatinine was observed in 55.2% of patients in placebo group (grade 1+2: 34.5%; grade 3: 20.7%) and 64.3% in NAC group (grade 1+2: 46.4%; grade 3: 17.9%) [Chi-square test, p=0.6517]. Moreover, reduced creatinine clearance was observed in 96.6% of patients in placebo group (grade 1+2: 75.9%; grade 3+4: 20.7%) and 96.4% in NAC group (grade 1+2: 82.1%; grade 3+4: 14.3%) [Fisher's exact test, p=0.8620].

Conclusion & Significance: Low-dose oral NAC did not attenuate cisplatin-induced nephrotoxicity. Further studies should be conducted to test other oral doses of NAC.